 "Drugmaker Roche to buy US' cancer medicine specialist Ignyta for $1.7 bn")
ZURICH (Reuters) - Roche has received authorisation from the United States' Food and Drug Administration (FDA) for its cobas 6800/8800 diagnostic tests for transplant patients, the company said on Wednesday.
The tests are used to detect Epstein-Barr virus DNA levels, linked to a range of diseases including cancer. The tests had previously been granted a breakthrough device designation by the FDA.
Also Read
(Reporting by John Revill; Editing by Kim Coghill)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
